Biomechanical Characterization of Skin Properties Using Impact Based-Analysis Method (IBAM): Malignant Cutaneous Tumors vs. Healthy Cutaneous Tissues
| Registry | NCT07861022, acronym SkinTumor-IBAM |
|---|---|
| Status | Not yet recruiting |
| Study type | Observational |
| Enrollment | 10 (Estimated) |
| Sponsor | Centre Hospitalier Universitaire Henri Mondor, Assistance Publique Hôpitaux de Paris (Other) |
| Conditions | Melanoma (Skin Cancer), Skin Carcinoma |
| Dates | start 2026-12-03 (estimated), primary completion 2027-12-01 (estimated), completion 2028-12-06 (estimated), first posted 2026-10-06, last updated 2026-10-06 |
Related Papers Related Patents Related Grants Related Experts
All trials for Melanoma (Skin Cancer) All trials for Skin Carcinoma
Skin palpation remains, alongside visual inspection, the main clinical tool used to detect cutaneous abnormalities. However, palpation is a subjective, operator-dependent examination with limited sensitivity. There is currently no simple, real-time, low-cost, non-invasive tool available in routine clinical practice to objectively characterize the mechanical properties of skin tissue.
The Impact-Based Analysis Method (IBAM) is a non-invasive biomechanical characterization technique developed by the MSME laboratory (Modélisation et Simulation Multi-Échelle, Université Paris Est Créteil) and the Mondor Institute for Biomedical Research (IMRB). It measures the mechanical response of soft tissue to a small mechanical impact, producing a quantitative indicator (Δt) that reflects local tissue stiffness. The reproducibility and sensitivity of this method have previously been demonstrated in preclinical models.
This study aims to evaluate whether IBAM can distinguish malignant cutaneous tumors (basal cell carcinoma, squamous cell carcinoma, melanoma) from healthy surrounding skin based on their mechanical properties, and to characterize how these mechanical properties evolve from the tumor center toward clinically healthy margins.
This is a prospective, single-center, ex vivo cohort study conducted at the Department of Plastic Surgery, Henri Mondor University Hospital (AP-HP), France. Patients undergoing surgical excision (with margins) for a suspected malignant cutaneous tumor will be included. Immediately after surgical excision, and before the specimen is sent for standard pathological examination, IBAM measurements will be performed ex vivo at three locations on the surgical specimen: the center of the tumor, the near peri-lesional area, and the distant peri-lesional area (presumed healthy margin). This additional step does not modify the patient's usual surgical or diagnostic management and does not require any additional intervention on the patient.
The primary objective is to compare the IBAM-derived mechanical indicator (Δt) between malignant tissue and healthy tissue, using paired measurements from the same surgical specimen. The secondary objective is to describe the progressive change in mechanical properties from the tumor center to the healthy margin, which may help define more objective surgical safety margins in the future.
A total of 10 patients will be included, based on a sample size calculation for a paired comparison (α = 5%, power = 80%). Statistical analysis will use paired Student's t-test or Wilcoxon signed-rank test, depending on data distribution (assessed by Shapiro-Wilk test).
This research does not fall under the French "Loi Jardé" framework for research involving the human person, as it involves no additional intervention beyond standard care. It complies with the CNIL reference methodology MR-004. Patients receive individual written information and provide written consent or non-opposition prior to inclusion. Data are pseudonymized and securely stored.
If confirmed, this method could provide surgeons with a simple, rapid, and objective tool to help differentiate malignant from healthy skin tissue intraoperatively, and to better define resection margins, with the ultimate goal of improving the surgical management of cutaneous malignancies.
Background and Rationale
Skin cancer is among the most frequent malignancies worldwide, and its incidence continues to rise. Early and accurate identification of tumor margins is essential both for diagnosis and for surgical planning, since incomplete excision increases the risk of local recurrence while unnecessarily wide excision increases morbidity, particularly in cosmetically or functionally sensitive areas.
In current clinical practice, the assessment of cutaneous lesions relies primarily on visual inspection and manual palpation. Palpation, in particular, is used empirically by clinicians to estimate tissue consistency and to help delineate the boundaries of a lesion. However, this examination is entirely subjective, strongly dependent on the experience of the examiner, and lacks any quantitative or reproducible basis. No simple, real-time, low-cost, non-invasive device is currently available in routine clinical practice to objectively characterize the mechanical properties of skin tissue and to assist clinicians in distinguishing pathological from healthy tissue.
Cutaneous tumors are known to exhibit altered biomechanical properties compared with healthy skin, reflecting changes in tissue composition, cellular density, and extracellular matrix organization. Several imaging and mechanical characterization techniques (elastography, indentation testing, suction devices) have been investigated to quantify these differences, but most require bulky equipment, are time-consuming, or are not adapted to intraoperative or bedside use.
The Impact-Based Analysis Method (IBAM) is a non-invasive, low-cost mechanical characterization technique developed collaboratively by the MSME laboratory (Modélisation et Simulation Multi-Échelle, UMR CNRS 8208, Université Paris Est Créteil) and the Mondor Institute for Biomedical Research (IMRB). The method relies on delivering a small, calibrated mechanical impact to the tissue surface and recording the resulting impactor motion. From this signal, a quantitative indicator (denoted Δt, corresponding to the time interval between successive impactor rebounds) is derived, which reflects the local stiffness and viscoelastic behavior of the underlying tissue. The device is portable, produces results in real time, requires no specific consumables, and involves no radiation or invasive procedure. Its reproducibility, spatial resolution, and sensitivity to changes in tissue mechanical properties have previously been established in preclinical (murine) models, including models of cutaneous neurofibromatosis.
Building on this preliminary work, the investigators hypothesize that IBAM measurements can discriminate malignant cutaneous tumor tissue from adjacent healthy skin, and that the mechanical signal progressively normalizes when measured at increasing distance from the tumor center. If confirmed, this would support the development of IBAM as a practical adjunct tool for intraoperative assessment of surgical margins.
Objectives
Primary objective: To determine whether malignant cutaneous tumor tissue (basal cell carcinoma, squamous cell carcinoma, or melanoma) can be differentiated from healthy cutaneous tissue based on mechanical properties measured by IBAM, using the Δt indicator as the primary outcome.
Secondary objective: To characterize the spatial evolution of the biomechanical signal from the center of the tumor toward increasingly distant peri-lesional areas, in order to explore the potential of IBAM to help define objective surgical safety margins.
Study Design
This is a prospective, single-center, ex vivo cohort study conducted within the Department of Plastic, Reconstructive and Aesthetic Surgery at Henri Mondor University Hospital (Assistance Publique - Hôpitaux de Paris, AP-HP), France. The study does not fall within the scope of the French law on research involving the human person ("Loi Jardé"), as it involves no modification of, or addition to, the patient's standard diagnostic or surgical care pathway. All measurements are performed ex vivo, directly on the surgical specimen, after excision and before transmission to the pathology department.
Study Population
Eligible patients are adults followed in the Department of Plastic Surgery at Henri Mondor University Hospital who present with a cutaneous lesion clinically or dermoscopically suspicious for malignancy (basal cell carcinoma, squamous cell carcinoma, or melanoma) and for whom surgical excision with safety margins is indicated as part of standard care.
Non-inclusion criteria:
Melanoma for which diagnostic excision has already been performed in sano prior to inclusion Cutaneous tumor related to a virally transmissible infection Ulcerated or fungating ("ulcéro-bourgeonnante") tumor
Based on a sample size calculation for a paired comparison design (two-sided alpha = 5%, statistical power = 80%), a total of 10 patients will be included. Recruitment is expected at a rate of approximately 2 to 6 patients per month, over an estimated inclusion period of 6 to 12 months.
Study Procedures
Patients meeting eligibility criteria are identified during routine dermato-plastic surgical consultation. Individual written information about the study is provided at the time of hospitalization (the day before or the day of surgery), and the patient's written consent or non-opposition is collected and documented, in accordance with the CNIL reference methodology MR-004.
Surgery proceeds according to the standard of care, with excision of the tumor and the surgically indicated safety margins. Immediately after excision, and before the specimen is transferred to the pathology laboratory for standard histological analysis, ex vivo IBAM measurements are performed directly on the surgical specimen at three predefined locations:
The center of the macroscopically visible tumor (malignant zone) The near peri-lesional area, close to the tumor edge The distant peri-lesional area, corresponding to the clinically healthy surgical margin
Measurements are recorded on a paper case report form at the time of testing, then transcribed the same day onto a secured, password-protected Excel file; the paper source is then destroyed. This additional ex vivo measurement step is performed without altering the specimen, without delaying or modifying its transmission to the pathology department beyond a negligible interval (estimated at less than one hour before fixation in formalin), and without any impact on the patient's subsequent management. The nature of the suspected tumor (from the pre-operative consultation report) and the final histopathological diagnosis (nature of the tumor, completeness of excision) are subsequently extracted from the institutional electronic medical record (ORBIS).
Outcome Measures
Primary endpoint: Variation of the Δt indicator (derived from the IBAM signal) between the malignant tumor zone and the healthy peri-lesional zone, measured on paired samples from the same surgical specimen.
Secondary endpoint: Trend of the Δt indicator across the three measurement locations (tumor center, near margin, distant margin), describing the spatial gradient of mechanical properties from the lesion to healthy tissue.
Statistical Analysis
The normality of data distribution will first be assessed using the Shapiro-Wilk test. Paired comparisons between the malignant and healthy zones will then be performed using the paired Student's t-test if data are normally distributed, or the Wilcoxon signed-rank test otherwise. A two-sided p-value below 0.05 will be considered statistically significant.
Data Management and Confidentiality
Personal data are collected exclusively from the patient's medical record (consultation report and histopathology results, via the institutional ORBIS system) and from the dedicated ex vivo mechanical measurements performed for the study. No data from the French National Health Data System (SNDS) are used. Data are pseudonymized using a patient identification number; the correspondence table linking this number to patient identity is accessible only to the coordinating investigator and the scientific lead. Pseudonymized data are stored on a password-protected Excel file, on a password-protected computer, in a locked office at Henri Mondor University Hospital. Data will be retained for 2 years. This research complies with Regulation (EU) 2016/679 (GDPR) and with the CNIL reference methodology MR-004 for studies not involving the human person.
Ethical and Regulatory Aspects
The study has been submitted for review to the Ethics Committee (IRB) of Henri Mondor University Hospitals. The sponsor (responsable de traitement) is Assistance Publique - Hôpitaux de Paris (AP-HP), represented by the Délégation à la Recherche Clinique et à l'Innovation (DRCI); the coordinating investigator (responsable de la mise en œuvre) is the physician responsible for the scientific conduct and data handling of the study within the Department of Plastic Surgery at Henri Mondor University Hospital.
Expected Significance
By providing a simple, real-time, low-cost, and non-invasive means of objectively characterizing the mechanical properties of cutaneous tissue, this study may contribute to the development of a practical adjunct tool for surgeons to help differentiate malignant from healthy skin tissue and to support more objective, standardized definition of surgical resection margins - ultimately aiming to improve the diagnostic and therapeutic management of patients with cutaneous malignancies.
| Arm | Type | Interventions | Description |
|---|---|---|---|
| Malignant skin tumor diagnosed patients | Patients with a suspected malignant cutaneous tumor (basal cell carcinoma, squamous cell carcinoma, or melanoma) undergoing surgical excision with safety margins at the Department of Plastic Surgery, Henri Mondor University Hospital. Immediately after excision, ex vivo biomechanical measurements are performed on the surgical specimen using the Impact-Based Analysis Method (IBAM) at three locations: the tumor center (malignant zone), the near peri-lesional area, and the distant peri-lesional area (healthy margin). No additional intervention is performed on the patient; standard surgical and pathological management is unchanged. Paired measurements from the same specimen are compared to assess whether IBAM can differentiate malignant from healthy cutaneous tissue based on mechanical properties, and to characterize how these properties evolve from the tumor toward healthy margins. |
Sex: All
Inclusion Criteria:
* Adult patient followed in the Department of Plastic, Reconstructive and Aesthetic Surgery at Henri Mondor University Hospital
* Cutaneous lesion clinically or dermoscopically suspicious for malignancy (basal cell carcinoma, squamous cell carcinoma, or melanoma)
* Surgical excision with safety margins indicated as part of standard care
Exclusion Criteria:
* Melanoma for which diagnostic excision has already been performed in sano prior to inclusion
* Cutaneous tumor related to a virally transmissible infection
* Ulcerated or fungating ("ulcéro-bourgeonnante") tumor